TrialLancet (London, England)2025

Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study.

Alice P Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.